LAVA Therapeutics N.V.
LVTX
$1.54
$0.0251.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -32.55% | -60.20% | 77.01% | -18.89% | -69.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -32.55% | -60.20% | 77.01% | -18.89% | -69.51% |
| Cost of Revenue | -24.98% | -30.08% | -31.88% | 882.96% | 886.23% |
| Gross Profit | 22.76% | 13.35% | 57.06% | -542.88% | -220.91% |
| SG&A Expenses | -3.77% | 3.82% | -0.30% | -5.33% | -6.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.65% | -17.95% | -24.46% | -38.91% | -45.44% |
| Operating Income | 3.54% | 1.35% | 40.29% | 42.59% | 30.88% |
| Income Before Tax | -15.55% | 3.63% | 41.02% | 45.50% | 40.76% |
| Income Tax Expenses | 216.80% | 208.63% | 145.53% | 1.75% | -13.48% |
| Earnings from Continuing Operations | -17.59% | 1.73% | 39.88% | 45.23% | 40.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.59% | 1.73% | 39.88% | 45.23% | 40.57% |
| EBIT | 3.54% | 1.35% | 40.29% | 42.59% | 30.88% |
| EBITDA | 2.59% | 0.74% | 40.53% | 43.01% | 31.38% |
| EPS Basic | -16.46% | 3.35% | 40.95% | 46.32% | 41.27% |
| Normalized Basic EPS | -9.01% | 0.72% | 51.27% | 46.57% | 41.44% |
| EPS Diluted | -16.46% | 3.35% | 40.95% | 46.32% | 41.27% |
| Normalized Diluted EPS | -9.01% | 0.72% | 51.27% | 46.57% | 41.48% |
| Average Basic Shares Outstanding | 0.78% | 1.21% | 1.60% | 1.97% | 1.87% |
| Average Diluted Shares Outstanding | 0.78% | 1.21% | 1.60% | 1.97% | 1.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |